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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S192costs were included, the average cost per quality adjusted life year
amounted to V 17,441, but the uncertainty around both CE-ratios
was substantial.
Conclusions: Over a period of 52 weeks, with a CE-ratio of – V 107,505
per QALY from the societal perspective and a CE-ratio of V 17,441 per
QALY from the healthcare perspective, our study revealed a consid-
erable probability that exercise therapy added to GP care is cost saving
or cost effective as compared to GP care alone.
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RESULTS FROM A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE
EFFICACY AND SAFETY OF INTRA-ARTICULAR
ONABOTULINUMTOXINA FOR OSTEOARTHRITIS KNEE PAIN
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Purpose: The peripheral release of inﬂammatory mediators may sen-
sitize nociceptors, provoke central sensitization, and facilitate clinical
pain. Inhibition of the peripheral manifestations in knee osteoarthritis
(OA) by onabotulinumtoxinA (onabotA) may reduce the drive, central
consequences, and eventually clinical pain. Study objectives were to
determine the safety and efﬁcacy of a single intra-articular (IA) onabotA
injection in patients (pts) with painful knee OA.
Methods: Pts 40–75 y with knee OA (American College of Rheumatol-
ogy modiﬁed clinical classiﬁcation criteria; Kellgren-Lawrence grade I-
III) were enrolled in this 16-wk, single-center, double-blind, random-
ized, placebo-controlled, parallel-group phase 1b study. Pts were
stratiﬁed by baseline 14-day average daily worst pain score (ADWP;
4.0–9.0 [0–10 numeric rating scale]), and randomized (1:1) to ultra-
sound-guided injection of either onabotA (200 U) or placebo (saline).
Pts recorded worst daily pain for 2 wks before and 12 wks after injec-
tion (study visits: 1, 4, 8, 12 wks).
The planned primary efﬁcacy assessment was 14-day ADWP score
change from baseline, jointly analyzed for wks 4, 8, and 12 by repeated
measures analysis of covariance (RMANCOVA); secondary planned
efﬁcacy outcomes included Western Ontario McMaster (WOMAC) OA
Index (total, pain, and physical function scores) and pt global
impression of change (GIC). Other planned outcomes included the
PainDETECT questionnaire (PD-Q), assessed at baseline and each visit.
3 pain subtypes have been deﬁned by total PD-Q score: nociceptive
(PD-Q score 12), neuropathic (19), and uncertain (13 and 18).
Unplanned post-hoc analyses of primary and secondary outcomes by
baseline PD-Q pain subtype were performed. Safety data were col-
lected, including muscle strength around the knee (knee extension/
ﬂexion, ankle dorsiﬂexion/plantarﬂexion) for the study side and the
contralateral side.
The primary efﬁcacy assessment (intent-to-treat population) was ana-
lyzed using RMANCOVA for between-group comparisons, adjusted for
baseline ADWP score. Secondary efﬁcacy variables were analyzed with
a Wilcoxon rank-sum test; WOMAC analyses did not use a baseline
covariate. The safety population included all pts who received drug. All
randomized pts received the assigned drug.
Results: Of 170 screened pts, 121 were randomized to onabotA (n ¼ 61)
or placebo (n¼ 60). Mean agewas 62.3 y, all Caucasian, and comparable
male (n ¼ 59) and female (n ¼ 62) participation. No clinically relevant
between-group differences were observed at baseline.
The primary efﬁcacy analysis yielded no signiﬁcant difference between
onabotA and placebo for the change from baseline in ADWP score to the
3 prospectively deﬁned time points (P ¼ 0.70). Between-group differ-
ences were also not signiﬁcant for ADWP score change from baseline to
each individual time point (each of wks 2–12), WOMAC (total index,
pain, or physical function scores at wks 1, 4, 8, 12), or GIC (wks 1, 4, 8,
12). Post-hoc analyses by PD-Q pain subtype found numerically greater
improvement for all efﬁcacy outcomes among pts with nociceptive pain
(PD-Q12) who received onabotA (n ¼ 36) versus placebo (n ¼ 32)
across all time points (Figure); signiﬁcant differences were seen at wk 8
and/or 12 for all WOMAC outcomes and GIC.Adverse events (AEs) were reported for 24 pts (39.3%) receiving ona-
botA and 27 pts (45.0%) receiving placebo. Treatment-related AEs were
reported for both onabotA (arthralgia, n¼ 1 [1.6%]; burning sensation, n
¼ 1 [1.6%]) and placebo (n ¼ 1 [1.7%] each: arthralgia, arthropathy,
hypoaesthesia, joint stiffness, joint warmth, muscular weakness); all
were mild. Muscle strength evaluations found no decrease from base-
line in any knee or ankle extension/ﬂexion measure in either group at
any visit.
Conclusion: This exploratory study found no signiﬁcant between-
group differences in primary or secondary efﬁcacy endpoints;
improvement from baseline was observed for both treatment groups.
Post-hoc analyses found numerically greater improvement for all efﬁ-
cacy endpoints among the PD-Q nociceptive pain subtype that received
onabotA versus placebo, suggesting the PD-Q may be useful in identi-
fying onabotA-responsive pts with knee OA pain. Locally administered
onabotA (200 U IA) had an acceptable safety proﬁle and did not
decrease muscle strength around the knee. Further evaluation of ona-
botA efﬁcacy among pts with nociceptive knee OA pain is needed to
conﬁrm these post-hoc ﬁndings.
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PHYSIOTHERAPIST-DELIVERED EXERCISE AND PAIN COPING SKILLS
TRAINING IS MORE EFFECTIVE THAN EITHER INTERVENTION
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Purpose: Pain is often the primary symptom of knee osteoarthritis (OA)
and results from a complex interaction between structural changes,
physical impairments and psychological factors. Much evidence sup-
ports the beneﬁts of strengthening exercise in this patient population.
There is also limited research supporting psychologist-delivered pain
coping skills training (PCST), a form of cognitive behavioural therapy, in
knee OA. Though typically provided separately, there are potential
symptom-, resource- and personnel-advantages of exercise and PCST
being delivered together by a single healthcare professional. Physi-
otherapists are a logical choice to be trained to deliver a PCST inter-
vention as they already have expertise in administering exercise and are
cognisant of the need for a biopsychosocial approach to management.
This study aimed to investigate whether an integrated 12-week exercise
and PCST treatment program delivered by physiotherapists is more
efﬁcacious than either program alone in treating pain and physical
function in individuals with knee OA.
Methods: The study utilized a 3-arm randomized controlled trial design
with measurements taken by a blinded assessor at baseline, 12, 32 and
52weeks following randomization. Twelveweeks was the primary time
